Epana Bio offers a high‑throughput single‑cell multi‑omics and AI platform that maps patient‑specific immune cell dysfunction in autoimmune diseases to identify druggable molecular targets. The system automates design of tailored biologics or small‑molecule candidates and integrates rapid preclinical validation, enabling pharma and biotech partners to develop mechanism‑based therapies with reduced side effects.
Funding
$320K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for autoimmune diseases rely on broad immunosuppression, which often fails to address the underlying cellular drivers of pathology and can cause significant side effects. The heterogeneity of immune cell dysfunction across patients makes it difficult to develop one-size‑fits‑all therapies, leading to suboptimal efficacy and delayed disease control.
Solution
Epana Bio applies high‑throughput genomics and machine‑learning pipelines to map the cellular origins of autoimmune disorders at the patient level. By integrating single‑cell transcriptomics, epigenomics, and clinical phenotypes, the platform pinpoints disease‑specific molecular targets for each individual. These insights feed an automated drug‑design engine that generates targeted biologics or small‑molecule candidates optimized for the identified pathways. The resulting therapeutics are intended to modulate the pathogenic immune cells while sparing normal immunity, thereby improving efficacy and reducing adverse events. Epana Bio accelerates the end‑to‑end discovery cycle through parallel in‑silico screening and rapid preclinical validation, shortening timelines compared with conventional approaches.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking to develop next‑generation, mechanism‑based therapies for autoimmune diseases, as well as academic research groups focused on translational immunology.
Features
- Single‑cell multi‑omics profiling pipeline that captures patient‑specific immune cell signatures
- AI‑driven target de‑risking model that ranks candidate pathways based on disease relevance and druggability
- Automated molecular design suite for antibody, peptide, and small‑molecule generation tailored to identified targets
- Integrated preclinical workflow combining in‑vitro functional assays and organ‑on‑chip models for rapid efficacy testing
- Biomarker‑guided patient stratification framework to match therapies with the most responsive subpopulations
- Secure cloud‑based data platform compliant with HIPAA and GDPR for collaborative research and analytics
- Scalable manufacturing roadmap leveraging modular biologics production to support personalized dosing regimens